Drs. DeVita and Greenberger have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors. Dr. Evens is an advisory board member of, received honoraria from, and receives grant/research support from Seattle Genetics, Inc. Dr. Rosen is a scientific advisor for Seattle Genetics, Inc.
Dr. Petrich receives grant/research support from, is a consultant for/receives honoraria from, and is on the product/speakers’ bureau for Seattle Genetics, Inc.; Genentech, Inc.; Spectrum Pharmaceuticals, Inc.; and Celgene Corporation. He receives grant/research support from Millennium Pharmaceuticals, Inc.
Kerrin M. Green, MA, Assistant Managing Editor, JNCCN—Journal of the National Comprehensive Cancer Network
Ms. Green has disclosed that she has no relevant financial relationships.
Deborah J. Moonan, RN, BSN, Director, Continuing Education & Grants
Ms. Moonan has disclosed that she has no relevant financial relationships.
Ann Gianola, MA, Manager, Continuing Education & Grants
Ms. Gianola has disclosed that she has no relevant financial relationships.
Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information Operations
Ms. Gregory has disclosed that she has no relevant financial relationships.
Castells MC, Tennant NM, Sloane DE et al.. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008;122:574–580.
Morton LM, Wang SS, Devesa SS et al.. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006;107:265–276.
Savage KJ, Harris NL, Vose JM et al.. ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008;111:5496–5504.
- Search Google Scholar
- Export Citation
. Savage KJ Harris NL Vose JM ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008; 111: 5496– 5504.
Swerdlow SH, International Agency for Research on Cancer, World Health Organization. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th ed. Lyon, France: International Agency for Research on Cancer; 2008.
Schmitz N, Trumper L, Ziepert M et al.. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010;116:3418–3425.
Gascoyne RD, Aoun P, Wu D et al.. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999;93:3913–3921.
Sibon D, Fournier M, Briere J et al.. Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte trials. J Clin Oncol 2012;30:3939–3946.
Benner MF, Jansen PM, Meijer CJ, Willemze R. Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders. Br J Dermatol 2009;161:121–127.
Bekkenk MW, Geelen FA, van Voorst Vader PC et al.. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000;95:3653–3661.
- Search Google Scholar
- Export Citation
. Bekkenk MW Geelen FA van Voorst Vader PC Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000; 95: 3653– 3661.
Kewalramani T, Zelenetz AD, Teruya-Feldstein J et al.. Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol 2006;134:202–207.
Rodriguez J, Munsell M, Yazji S et al.. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 2001;19:3766–3770.
Shipp MA, Abeloff MD, Antman KH et al.. International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin’s Lymphomas: report of the jury. J Clin Oncol 1999;17:423–429.
de Claro RA, McGinn K, Kwitkowski V et al.. U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res 2012;18:5845–5849.
Doronina SO, Toki BE, Torgov MY et al.. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nature Biotechnol 2003;21:778–784.
Sutherland MS, Sanderson RJ, Gordon KA et al.. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem 2006;281:10540–10547.
Francisco JA, Cerveny CG, Meyer DL et al.. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003;102:1458–1465.
Pro B, Advani R, Brice P et al.. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012;30:2190–2196.
Younes A, Bartlett NL, Leonard JP et al.. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363:1812–1821.
Baxley AA, Kumm DE, Bishop CB et al.. Severe infusion reactions to brentuximab vedotin in two patients with Hodgkin lymphoma previously treated with allogeneic stem cell transplantation. J Oncol Pharm Pract 2013;19:279–283.
Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Drugs 2003;63:803–843.
Byrd JC, Waselenko JK, Maneatis TJ et al.. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 1999;17:791–795.
DeNardo GL, Bradt BM, Mirick GR, DeNardo S. Human antiglobulin response to foreign antibodies: therapeutic benefit? Cancer Immunol Immunother 2003;52:309–316.
Khazaeli MB, Conry RM, LoBuglio AF. Human immune response to monoclonal antibodies. J Immunother Emphasis Tumor Immunol 1994;15:42–52.